North Central Cancer Treatment Group Trial N0733 for HER2 Positive Breast Cancer Teleconference
Posted on March 9th, 2009 by erailey
You are cordially invited to join Dr. Paul Haluska in a teleconference for an update on and to discuss your questions/comments about the North Central Cancer Treatment Group Trial N0733 for HER2 positive breast cancer patients who have had their cancer back or grow through first line treatment with Herceptin. In this trial, we are adding a new drug (IMC-A12- an IGF-1R inhibitor) to the standard therapy for this patient population (Lapatinib + capecitabine). Pre-clinical experience indicates that this combination is much better than the sum of the parts. To join the call on March 11 at 2 p.m. CST, please call: 1-866-365-4406 (toll-free); Participant Code: 2844481
